Johnson and Johnson (J&J) recently filed a motion to dismiss in the antitrust claim brought against the company by Walgreen and Kroger in regard to sales of J&J’s reference infliximab product, Remicade. In early December, the District Court for the Eastern District of Pennsylvania denied the motion.
Johnson and Johnson (J&J) recently filed a motion to dismiss in the antitrust claim brought against the company by Walgreen and Kroger in regard to sales of J&J’s reference infliximab product, Remicade. In early December, the District Court for the Eastern District of Pennsylvania denied the motion.
In June 2018, Walgreen and Kroger filed an antitrust suit against J&J and its Janssen division seeking permanent injunctive relief and damages “arising out of [J&J and Janssen’s] unlawful exclusion of biosimilar competition to the brand name drug Remicade,” according to the suit.
The suit is similar to another antitrust suit filed by Pfizer against J&J in November 2017 in the same court. According to the suit, when Pfizer earned FDA approval for its infliximab biosimilar, Inflectra, it sold the product at a 15% discount to the wholesale acquisition cost (WAC) of the brand name drug. In addition, Merck also received FDA approval for its own biosimilar infliximab, Renflexis, in the same year which was sold at a 35% discount to the WAC cost of Remicade.
Despite the introduction of 2 lower-priced products, J&J maintained its hold on the market and limited its competitors to single-digit market share and has been able to increase the price of Remicade since the introduction of the biosimilars.
Walgreen alleged that J&J’s hold on the market is due to exclusionary practices enacted through “contracts and bundled discounts that have suppressed competition.” Furthermore, the suit states that J&J entered into agreements with insurers through which they agreed not to cover either of the biosimilar products on their respective plans, or to only do so in rare cases.
According to the order of dismissal, J&J moved to dismiss Walgreens and Kroger’s claim on 2 grounds: J&J alleged that the retailers’ claims did not sufficiently allege antitrust violations, and that because the retailers do not have consent from the distributors to pursue these claims, they lacked antitrust standing.
On the first ground, the court found that, similar to the case brought by Pfizer, the complaint “plainly and repeatedly emphasizes that, as a result of the anticompetitive behavior,” the plaintiffs have “paid inflated prices for those products.”
Finally, in regard to the second ground, the Court converted J&J’s motion into one for summary judgement, and will hear additional evidence and briefing. “Motions must be submitted within 45 days and any factual development shall be limited to whether the assignment to Retailer Plaintiffs was valid,” read the order.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.